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ABSTRACT Prophylaxis and treatment of inherited clotting disorder hemophilia A requires regular administra-
tion of factor VIII. Recombinant factor VIII, which is produced in CHO or BHK cells, is equivalent to the plasma-
derived one and is prevalent in current clinical practice in developed countries. Development of a biosimilar 
recombinant FVIII requires the creation of a highly productive clonal cell line and generation of monoclonal 
antibodies suitable for affinity purification of the product.  Methotrexate-driven transgene amplification of 
genetic cassettes that code full-length and truncated variants of FVIII under the control of the CMV promoter 
was studied. It was shown that the expression level of the truncated variant of FVIII is 6.5 times higher than that 
of the full-length molecule. The transgene amplification procedure was sufficient for a twofold increase of the 
expression level in the transfected cells pool and subsequent selection of the clonal line, stably producing trun-
cated FVIII at the level of 0.52 IU/ml during cultivation in a chemically defined protein-free culture medium. 
Four generated mouse monoclonal antibodies toward the heavy chain of FVIII were found suitable for binding 
the truncated variant of FVIII directly from the conditioned medium and elution of the FVIII with a more than 
85% yield and normal pro-coagulant activity.  The producer cell line and monoclonal antibodies obtained are 
sufficient for the development of upstream and downstream processes of biosimilar FVIII production. Genera-
tion of more productive cell lines by the use of stronger, nonviral promoters and shorter cDNA of FVIII will be 
the subject of further studies. 
KEYWORDS coagulation factor VIII; B-domain deleted factor VIII; hemophilia A; heterologous protein expres-
sion systems.
ABBREVIATIONS FVIII – blood clotting factor VIII; rhFVIII – recombinant human FVIII, BDD-FVIII – FVIII 
with deleted B-domain, MTX - methotrexate, EG - ethylene glycol, EMCV - Encephalomyocarditis virus, IRES - 
internal ribosome entry site, DHFR - dihydrofolate reductase (EC 1.5.1.3); IU – international unit (1 IU of FVIII 
corresponds to its content in 1 ml of pooled donor plasms), ORF – open reading frame, PBS – phosphate buffered 
solution.
INTRODUCTION
Blood clotting factor VIII (FVIII) is a nonenzymatic 
cofactor for factor IXa forming a complex that binds 
factor X and activates it, realizing a major amplifica-
tion loop of the blood coagulation cascade. Defects in 
the gene of FVIII result in hemophilia A, a recessive 
X-linked coagulation disorder with a prevalence of 1 
case per 5,000 males.
Protein substitution therapy, performed on a regu-
lar basis, is the only effective treatment for hemophil-
ia A. the traditional source of FVIII is donated blood 
plasma, which is in short supply and poses a significant 
risk of virus [1, 2] and prions [3] transmission, even af-
ter rigorous plasma batches screening and multiple 
viral inactivation procedures. recombinant human 
FVIII (rhFVIII) for hemophilia A treatment may be 
obtained from cultured mammalian cells purified to 
clinical grade by affinity chromatography and three 
or four rounds of conventional chromatography and 
virus-inactivated by solvent-detergent treatment and 
nanofiltration or heating. Marketed variants of rhFVIII 
are expressed in chinese hamster ovary (cHO) or baby 
hamster kidney (BHK) cells and are fully equivalent to 
the plasma-derived FVIII in replacement therapy.94 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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the major drawback of rhFVIII production tech-
niques is the low expression level, which is caused by 
the unusual size and structural complexity of the target 
protein. natural human FVIII is a 170- to 280-kDa gly-
coprotein, mainly present in circulation in the form of a 
noncovalent complex with the chaperone - von Wille-
brand factor (vWF) in a concentration of approximately 
400 ng/ml.  FVIII is expressed in the liver as a single-
chain polypeptide containing the A1-A2-B-A3-c1-c2 
domains. the mature, secreted protein is cleaved in 
the region between the B and A3 domains and forms a 
heterodimer of 90-200 kDa, heavy chain (A1-A2-B do-
mains), and 80 kDa, light chain (A3-c1-c2 domains) [4]. 
A significant part of the FVIII molecule, the B-domain, 
may be deleted without compromising the clotting ac-
tivity and plasma half-life of the truncated FVIII [5]. 
replacement of the B-domain by the short linker pep-
tide called SQ results in a significant increase in the rh-
FVIII expression level in cHO cells and the complete 
processing of the precursor protein to its mature form 
[6]. the B-domain-deleted FVIII (BDD-FVIII), which 
is marketed under the trade name reFacto, has shown 
comparable efficiency with full-length FVIII variants 
and is as safe [7]. 
the aim of the present study was to generate a clon-
al cell line secreting rhFVIII at a significant level and 
to develop monoclonal antibodies for affinity purifica-
tion of rhFVIII. Since the ability of  cell lines bearing a 
single-copy genomic insert to produce enough rhFVIII 
has not been confirmed in published studies, FVIII or 
BDD-FVIII coding vectors suitable for insertion cas-
sette amplification were evaluated.
EXPERIMENTAL PART
Construction of expression plasmids: 
For pOptivec/F8 construction, pOptivec plasmid de-
rived from a re-ligated linear pOptivec-tOPO vector 
(Invitrogen, uSA) was restricted by NotI and ligated 
by t4-ligase with a NotI-NotI fragment of pcMV6-
XL4/nM_000132 containing the full factor VIII gene 
(Origene, uSA). the enzymes used were acquired from 
Fermentas, Lithuania, or Sibenzyme, rF.
For BDD-FVIII generation, the Pcr fragments F1 
(479 b.p.) and F2 (933 b.p.) that flank the deleted region 
were obtained using the primers O1KpnIfor, O1Hin-
drev and O2Hindfor, and O2Blprev, respectively (Sup-
plementary Table 1). Oligonucleotides were synthesized 
by evrogen JSc, rF. Pcr was performed by a tersus 
polymerase mix (evrogen JSc, rF) on the Ptc-100 
Table 1. Primers used for FVIII-SQ BDD mutant construc-
tion. Restriction sites are underlined
O1KpnIfor 5’GctGGtAcctcAcAGAGAAtAtAcA3’
O1HindIIIrev 5’GGAGAAGcttcttGGttcAAtG3’
O2HindIIIfor 5’ccAAGcttctcccAAAAcccAccA 
GtcttGAAAc3’
O2BlpIrev 5’ctGcccAtGctGAGcAGAtAc3’
Odelf 5’GccAcAActcAGActttcG3’
8sq4f 5’tGtAtttGAtGAGAAccGAAGc3’
8sq5r 5’GccActctGAGccctGtt3’
cMVfor 5’cGcAAAtGGGcGGtAGGcGtG3’
8sq15r 5’GAGttctttGtttctGAGtGcc3’
Table 2. Primers used for sequence analysis of FVIII ORF
8sq1f tGAtcAGAccAGtcAAAGGGA
8sq2f GAttGGAtGccAcAGGA
8sq3f GccctcAGcGGAttGGt
8sq4f tGtAtttGAtGAGAAccGAAGc
8sq5f tGccAttGAAccAAGAAGc
8sq6f GAGAAActGGGGAcAActGc
8sq7f AGAAAGActcAcAttGAtGGcc
8sq8f AcAAAGtGGtAGtAGGAAAGGGtG
8sq9f tGAAAcAAttcAGActcccAct
8sq10f GAcAAGtGccAcAAAttcAG
8sq11f tttGtccctGAAcGcttGt
8sq12f cAGcccttAtAccGtGGAG
8sq13f cAGAtGGAAGAtcccActtt
8sq14f GGAtcAAtcAAtGcctGGAG
8sq15f AGGAGtAAtGcctGGAGAcc
8sq1re GcAAGccAGGGAGGGAc
8sq2re tGGcAAAcAtAttGGtAAAGtA
8sq3re AGGGGAGtctGAcActtAttGc
8sq4re GAGcAAAttcctGtActGtcActt
8sq5re GccActctGAGccctGtt
8sq6re cttGGGAtttccActcttcttt
8sq7re ctGctGGAAGAtGAGAAGAGtt
8sq8re tGctGGcttGtAttAGGAGA
8sq9re GccttGcccAGAGttcAG
8sq10re AGtcAAcAAAGcAGGtccAt
8sq11re ActGtctAttGctccAGGtGA
8sq12re ctGAGAAtGGGAAtAGGGtGA
8sq13re GGGtcAGGcAccGAGGA
8sq14re GGAtGcttcttGGcAActGA
8sq15re GAGttctttGtttctGAGtGcc
IreSArev AGGtttccGGGccctcAcAttGreSeArcH ArtIcLeS
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thermal cycler (MJ reseach, uSA); purified Pcr 
products were cloned to the pAL-tA vector (evro-
gen JSc, rF) and fully sequenced using the BigDye 
terminator v. 3.1 cycle sequencing kit (Applied Biosys-
tems, uSA), a ABI PrISM 3730 genetic analyzer (Ap-
plied Biosystems, uSA), and the chromas 1.45 program 
(technelysium Pty Ltd, Australia) for data analysis.
the n-terminal FVIII gene fragment F3 was ob-
tained by pcMV6-XL4/nM_000132 restriction with 
the NotI and KpnI enzymes. Assembly of the fragments 
F1-3 was performed in the PAL-tA vector by corre-
sponding restriction enzymes resulting in pALtA/
F123. Pcr for clone analysis was performed with the 
Odelf specific primer and the vector-specific M13for 
and M13rev primers. 
the BlpI-BlpI fragment of the pOptivec/F8 plasmid 
was exchanged for the BlpI-BlpI restriction fragment 
of pALtA/F123, resulting in the pOptivec/F8BDD 
plasmid. Pcr for clone analysis was performed with 
two specific primer pairs: 8sq4f, 8sq5r and cMVfor, and 
8sq15r. the OrFs of full-length FVIII and BDD-FVIII 
and expression vector functional elements (promoter, 
IreS, terminator) were sequenced using the specific 
primers listed in Supplementary table 2.
Preparation of the assembled plasmids for transfec-
tion was done by transformation to a Stbl4 E. coli strain 
(#11635018 Invitrogen, uSA), cultivation in a 0.5 L tB 
broth for 18 h, and purification by the endoFree Plas-
mid MaxiKit (Qiagen, uSA). For stable cell lines gener-
ation, plasmids were linearized by PvuI restriction, fol-
lowed by ethanol precipitation. the precipitates were 
dissolved in PBS and filter-sterilized using 0.22 µm fil-
ters (Millipore, uSA).
cell culture: A DHFr-negative chinese Hamster 
Ovary cHO DG-44 cell line (Invitrogen, uSA) main-
tained in a chemically defined suspension medium was 
used. the cells were cultivated in a suspension culture 
as 30 mL batches in erlenmeyer flasks (VWr, uSA), 
with a cD DG-44 medium (Invitrogen, uSA) supple-
mented with 8 mM L-glutamine (Invitrogen, uSA) 
and 0.18% Pluronic F-68 (BASF Inc., uSA). the cul-
ture flasks were maintained in a humidified incubator, 
37°c/8% cO2 on a shaker, at a constant rotation rate 
of 130 rpm. Viability by trypan blue exclusion assay 
was assessed and cell count performed at each cell pas-
sage. cells were passaged every 2-3 d and maximum 
cell concentration was set at 1.2x106 viable cells in 1 ml: 
split ratio 1:4. 
transfection and selection of stably transfected cells: 
transfection was performed by the animal origin free 
reagent Lipofectamine 2000 (Invitrogen, uSA) using 
18 µg of linearized plasmid DnA per 1,5x107 cells in 
30 mL of the culture medium. cells were cultivated 
48 h post-transfection without medium change, then 
they were transferred to the selection nucleoside-free 
medium cD OpticHO (Invitrogen) supplemented with 
8 mM L-glutamine (Invitrogen, uSA) and cultivated 
until cell viability reached 90% (10-20 d). During culti-
vation in the selection medium, the cells were passaged 
every 3 d or at a concentration of 3x105 cells/mL. the 
levels of FVIII secretion were determined 48 h after 
transfection and at the end of cultivation in the selec-
tion medium. three independent transfections were 
performed in the same conditions for each plasmid. the 
highest producing pool was selected for the methotrex-
ate (MtX) induced amplification of dhfr and the FVIII 
genes.
clonal cell lines generation: the selected pool of sta-
bly transfected cells was subjected to growth in the 
presence of increasing concentrations of methotrexate 
in a cD OpticHO medium supplemented with 8 mM 
L-glutamine. At every subsequent step of the MtX-
driven target gene amplification, the concentration 
of MtX was increased twofold. On each step, the cells 
were cultivated for at least 10 days, then 4 to 15 more 
days until cell viability reached 90%. the levels of se-
creted FVIII were measured by eLISA at the end of 
each step. the highest producing amplified pool was 
used for obtaining clonal cell lines by limiting dilution 
at 0.5 cells/well. cloning was performed in the adher-
ent culture, utilizing a medium cD cHO-A (Invitrogen, 
uSA) (200 µl/well) containing 8 mM GlutaMAX (Inv-
itrogen, uSA) at 37°c/ 5% cO2 for 21 days. MtX was 
excluded from the cloning medium and was not used in 
further cultivation. 
the growth of single colonies in wells was monitored 
and documented on days 10 and 14. the colonies were 
transferred to 48-well plates, and the conditioned me-
dium from the wells with actively grown colonies was 
assayed by eLISA. the best secreting cell clones were 
further propagated in the adherent conditions and re-
adapted to the suspension culture in 3 consecutive pas-
sages in 24-, 12-, and 6-well plates, utilizing a cD Opti-
cHO medium with 8 mM L-glutamine. the conditioned 
medium from 6-well plates was screened by eLISA; 
one clonal line was selected and expanded further by 
subsequent passages in 3, 15, 100, and 200 mL of cD 
OpticHO.
Small-scale production culture was done in shak-
ing flasks at a 200-mL scale. cells were seeded at 
2,5x105 cells/mL, cultured without medium change to 
a density of 3x106 cells/mL (4-5 days), and then cul-
tured for 3 more days with a daily addition of 4 mM 
glutamine and 3 mM glucose. cell mass and debris were 
removed by centrifugation at 500 g for 5 min and sub-
sequent filtration of supernatant by 0, 22 µm PeS cap-
sule filter (Millipore, uSA). the clarified medium was 
stored frozen and thawed immediately before use. 96 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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eLISA: eLISA was performed as described in [8]. 
Antibody capture eLISA was used for the testing of 
anti FVIII mAbs, and a concentrate of plasma-derived 
FVIII (a generous gift from Dr. A.L. Berkovsky) in PBS 
at 200 ng/well was used for plate coating. Sandwich 
eLISA was utilized for secreted FVIII in the culture 
medium, polyclonal anti-FVIII antibodies (LifeSpan 
BioSciences, uSA) at 50 ng/well were used for plate 
coating, and in-house developed anti-FVIII murine 
mAb A2 was used for detection. Frozen pooled normal 
human plasma serially diluted in 1% BSA-PBS was 
used as a quantity calibrator. All the samples tested 
were applied to plates undiluted or diluted immediately 
before testing by 1% BSA-PBS. 
Western blotting: Whole-cell lysates were prepared 
with a modified rIPA buffer (50 mM tris-Hcl, pH 7.4; 
1% nP-40; 0.25% na-deoxycholate, 150 mM nacl, 1 mM 
eDtA) containing a protease inhibitor cocktail (Sigma, 
uSA). Samples of the conditioned medium were clarified 
by centrifugation and concentrated 30-fold by trichlo-
roacetic acid precipitation. the samples were normal-
ized by total protein concentration, applied at 10 µg of 
total protein per lane, and resolved on 7.5% SDS-PAGe 
gels. Protein transfer, blocking, hybridization, and color 
development were done according to [8] using a Hy-
bond c extra membrane (Ge Healthcare, uSA) and a 
3,3’,5,5’-tetramethylbenzidine substrate (Sigma, uSA). 
Generation of mAbs: Immunization, fusion, and clon-
ing of hybridomas were performed according to [8]. Fe-
male Balb/c mice (Harlan Labs, uK) were immunized 
subcutaneously with 100 ng of recombinant full-length 
FVIII (Kogenate FS) in 0.25 mL of 0.85% nacl and 
0.25 mL of complete Freund’s adjuvant. (Pierce Bio-
technology, uSA). two and four weeks after the initial 
injection, the animals were boosted with 100 ng of the 
same antigen in IFA. One week after the last injection, 
the mice were tail-bled and the serum antibody level 
was monitored by eLISA. One mouse with the highest 
titer of IgG was sacrificed for cell fusion. Splenocytes 
from the chosen mouse were fused with SP2/0 my-
eloma cells using polyethylene glycol. the fused cells 
were propagated in a selective medium, plated in 96-
well plates, and then screened for anti-fVIII IgG titer. 
the cells from positive wells were expanded to 24-well 
plates and screened for titer and sensitivity to elu-
tion by 50% ethylene glycol in PBS. the wells with the 
highest titers and highest sensitivity to ethylene glycol 
elution were used for hybridoma cloning by limiting 
dilution (0.5 cells/w). expanded hybridoma clones were 
re-screened by the same procedure and cloned again. 
the expanded clones were used for generation of the 
conditioned medium (10-100 mL) and ascites produc-
tion in pristane-primed Balb/c mice. the ascitic fluid 
collected was stored frozen for further use. 
Purification of monoclonal antibodies from the ascit-
ic fluid and conditioned medium was performed by the 
same protocol – precipitation by ammonium sulphate, 
Protein G affinity chromatography using a Hitrap Pro-
tein G HP (Ge Healthcare, uSA) 1 ml column, concen-
tration of eluted IgG by ultrafiltration, and polishing/
desalting by size exclusion chromatography utilizing a 
Superdex 75 10/300 column (Ge Healthcare, uSA) and 
PBS as the mobile phase.
nHS-activated Sepharose 4 Fast Flow (Ge Health-
care, uSA) was used for mAb’s coupling according to 
the resin manufacturer`s instruction. Antigen capture 
was performed in batch format, and 1 ml aliquots of 
the conditioned medium was mixed in microcentri-
fuge test tubes with 0.1 ml aliquots of affinity sorbents 
for 1 h at room temperature. Sorbents were settled 
by brief centrifugation, and the supernatants of the 
depleted medium were collected for further analy-
sis. Sorbents were washed by 3 1 ml portions of PBS; 
bound proteins were eluted by the addition of 0.15 ml 
of 50% ethylene glycol in the PBS solution and 5 min 
incubation. 
coagulation assay: the clotting assay for the fVIII 
level was performed on a thromboScreen 400c (Pa-
cific Hemostasis A Fisher Scientific company) optical 
coagulometer using the reagents kit “Factor VIII-test” 
(nPO renam, rF) according to the kit manufacturer’s 
protocol with some modifications. culture media sam-
ples were diluted ten times by imidazole solution prior 
to the analysis, and eluates from the affinity columns 
were diluted 10-50 times by a imidazole solution sup-
plemented with 1% BSA. For testing the conditioned 
media samples, calibration plasma samples were sup-
plemented by 10% of the conditioned medium from 
non-transfected cHO DG-44 cells. In case of affinity 
column eluates, the calibration samples were supple-
mented by 2-10% of the elution solution.
RESULTS AND DISCUSSION
An expression construct of the full-length factor VIII 
gene pOptivec/F8 was created on the base of the pOp-
tivec-tOPO vector. the SQ B-domain deletion mutant 
cloning strategy included minimization of the Pcr 
fragments length to bypass Pcr-mediated mutations. 
two short Pcr fragments, F1 and F2, flanking the de-
leted region were separately cloned and then assem-
bled with F3 - a restriction fragment of pcMV6-XL4/
nM_000132 corresponding to the n-terminal part of 
the FVIII protein. to obtain the expression plasmid, the 
pOptivec/F8BDD BlpI-BlpI fragment of the pOptivec/
F8 expression plasmid was exchanged for the BlpI-BlpI 
fragment of the obtained F123 assembly (Fig. 1). 
the resulting expression plasmid contained a strong 
cMV-promoter, a natural FVIII Kozak sequence, F8-reSeArcH ArtIcLeS
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BDD OrF, followed by a encephalomyocarditis virus 
(eMcV) internal ribosome entry site (IreS) that allows 
5’ cap-independent translation initiation: the dhfr gene 
which allows clonal selection of transfectants and fur-
ther MtX-driven amplification of the fVIII-IreS-dhfr 
cassette in dhfr- cells. For stable cell lines generation 
plasmids were linearized for destruction of the irrel-
evant ampicillin resistance gene. 
Generation of the producer cell line
transfection of DHFr-negative cHO DG-44 cells by 
linearized expression cassettes was performed in a 
serum-free medium utilizing an animal-origin free 
transfection reagent. transfection efficiency was es-
timated by transfection of the control plasmid coding 
fluorescent eGFP protein; 10 to 20% of the cells ex-
pressed eGFP at 48 h post-transfection, and cell viabil-
ity was above 85%. three rounds of transfection were 
performed for each FVIII-coding plasmid, and stable 
pools were obtained by cultivation of the transfected 
cells in a selective medium for 15-20 days. the levels of 
secreted FVIII were determined by eLISA; in the case 
of full-length FVIII, less than 10 Iu/l of secreted FVI-
II was found in all cell pools, and in the case of BDD-
FVIII, a stable transfectant pool with a 71±10 Iu/ml 
secretion level was found and used for transgene am-
plification. 
the pool of stably transfected cells was treated by 
MtX, starting at the 25 nM level. After stabilization of 
the culture, determined as improvement in cell viabil-
ity to more than 85%, the concentration of MtX was 
increased twofold and amplification continued (Fig. 2). 
It was found that a steady increase in the secreted 
BDD-FVIII level does not take place; the maximum 
BDD-FVIII level in the conditioned medium was at-
tained after 5 subsequent amplification steps (0,5 µM of 
MtX). Further increase of MtX concentration resulted 
in an immediate tenfold drop in the product secretion 
rate and subsequent increase to the values of the initial 
culture (74±6  Iu/l at 16 µМ MtX). It was suggested 
that non-producing cells containing altered bicistronic 
mrnA [9] or amplified non-relevant genes, for example 
the gene of multiple-drug resistance protein 1 [10], take 
over the producing population. 
the best producing cell pool, obtained at the level of 
0.5 µM MtX, was used for the generation of clonal cell 
pCMV6-XL4/ 
F8 13696  bp
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pOptivec/ F8 
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O1HindIIIrev
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pAL-F2 
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pAL-F1
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NotI-KpnI
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фрагмент 
(3242 bp)
+ pOptivec (circ.)
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Fig. 1. General molecular cloning scheme and map of the pOptivec/F8BDD expression plasmid.  Linear fragments 
shown as rectangles, plasmids – as circles. PCR steps are shown as dotted lines, restriction-ligation steps – as full lines. 
CMV-prom - cytomegalovirus promoter, F8 Kozak - natural Kozak sequence of the FVIII gene, F8 signal peptide – natu-
ral FVIII signal peptide sequence, F8BDD – ORF of the SQ B-domain deleted factor VIII, EMCV IRES - encephalomyo-
carditis virus internal ribosome entry site, dhfr - ORF of the dihydrofolate reductase, polyA – bovine growth hormone 
polyadenylation signal, pUC ori – bacterial replication origin, bla – ampicillin resistance gene, bla prom - ampicillin resist-
ance gene promoter. Directions of genes transcription are shown by arrows. Restriction sites used for cloning proce-
dures are in italics.98 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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lines by limiting dilution. twenty-two clones derived 
from the wells with single cell colonies and secreting 
the target protein according to eLISA were grown to 
more than 106 cells in the adherent culture conditions 
and analyzed for the concentration of secreted FVIII 
(Table 1). Four clones with the highest production rate 
were further cultivated in the suspension culture and 
tested again for the concentration of FVIII after three 
and ten consequent passages (10 and 30 days of con-
tinuous culturing). two clones, #18 and #22, showed no 
significant drop in FVIII production (data not shown), 
and the more productive clone #18 was chosen for sub-
sequent use. 
the conditioned medium from the chosen clonal cell 
line, designated DG-BDDFVIII-18, was used for the 
characterization of the secreted FVIII. According to 
Western blotting data (Fig. 3), the bulk of the secreted 
FVIII, as well as the intracellular precursor, was proc-
essed into the form of a two-chain protein. Low levels 
of the single-chain form were detectable only by the 
antibody toward the heavy chain, and no degradation 
products were detected by both antibodies, which is an 
indication of the proper short-term stability of FVIII in 
the culture medium used. 
the pro-coagulant activity of FVIII in the condi-
tioned medium was assessed based on its ability to de-
crease the clot time of the substrate plasma obtained 
from hemophilia A patients in the aPtt test. the ac-
tivity of FVIII in the conditioned medium tested was 
Table 3. Productivity of the 10 highest secreting clonal cell lines. Product concentration was measured for adherent cul-
tures at the attainment of confluence
clone number 18 22 17 9 1 2 15 3 4 16
Secreted FVIII , Iu/l  502 475 434 416 410 399 395 379 378 375
F
V
I
I
I
,
 
I
U
/
l
200
180
160
140
120
100
80
60
40
20
0
0  0.025  0.05  0.1  0.25  0.5  1  2  4  8  16
MTX, µМ
Fig. 2. Secretion level of BDD-
FVIII for confluent cell pools by 
ELISA. Samples in duplicates, 
error bars represent a 95% 
confidence interval.
0.47 Iu/ml, and the FVIII antigen level in the same 
sample was 0.52 Iu/ml according to eLISA data; here-
by, the recombinant FVIII secreted by the clonal cell 
line DG-BDDFVIII-18 has full specific activity.
the known industrial purification process for the 
BDD-FVIII protein consists of 4 stages of conventional 
chromatography and one round of affinity purifica-
tion [11]. therefore, the key element in the process is 
the monoclonal antibody, which is capable of capturing 
BDD-FVIII from the culture medium or from the in-
termediate concentrate and of subsequently releasing 
the product under mild elution conditions. the typical 
solution suitable for the elution of FVIII from immuno-
affinity columns is PBS with 50% ethylene glycol [12].
A monoclonal antibody suitable for the affinity puri-
fication of BDD-FVIII was obtained by screening anti-
FVIII hybridoma clones by eLISA, in which the wells 
were washed three times with a 50% ethylene glycol 
solution after the incubation of hybridoma culture su-
pernatants and the control wells were washed with a 
PBS-tween solution. the target clone is expected to 
show a significant signal decrease upon ethylene gly-
col wash. Out of the 34 individual clones derived from 
one cell fusion, four clones with a high mAb titer and 
the highest sensitivity to ethylene glycol wash were se-
lected (Table 3). 
All of the four mAbs selected recognized the heavy 
chain of BDD-FVIII on western blotting; i.e., their 
epitopes do not belong to the B-domain of FVIII. Pu-reSeArcH ArtIcLeS
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Table 4. Properties of ethylene glycol-sensitive mAbs
clone  
name
mAb titer  
in the ascitic fluid
Decrease in eLISA  
signal at ethylene  
glycol wash, %
resin binding capacity, 
Iu/ml
FVIII elution degree,  
%
A2 1:123 000 40% 2.6 89%
e3 1:68 500 39% 2.8 89%
A4 1:27 500 15% 1.6 >90%
B6 1:123 000 35% 3.4 86%
heavy chain   light chain
medium      cells       medium  cells
BDD-FVIII    -      +       -      +         -     +     -    +
170-
130-
95-
72-
43-
34-
-170
-130
-95
-72
-43
-34
Fig. 3. Western blotting of secreted and intracellular 
BDD-FVIII. “Heavy chain” and “light chain” – probing by 
antibodies toward heavy and light chain, “BDD-FVIII -” 
and “BDD-FVIII +” – samples from nontransfected CHO 
DG-44 cells and cell line DG-BDDFVIII-18, respectively. 
SDS-PAGE in reducing conditions, molecular weights are 
shown in kDa.
rified mAbs were obtained from the ascitic fluid and 
immobilized on nHS-activated Sepharose at 1 mg of 
mAb per 1 ml of the settled resin ratio. Immunosorb-
ents were used to capture BDD-FVIII directly from 
the conditioned culture medium with 1 h batch adsorp-
tion. Adsorption of BDD-FVIII in these conditions was 
incomplete (ca. 20-30%), but nearly the entire bound 
product was retained notwithstanding PBS wash and 
eluted with the 50% ethylene glycol solution. the levels 
of FVIII in the nonbound fractions and eluates were 
measured by plasma clot assays. the presence of bio-
logically active FVIII in the eluates indicates that the 
elution conditions used did not significantly degrade 
the product. thus, several mAbs suitable for large-
scale affinity purification of recombinant FVIII were 
obtained.
CONCLUSIONS
the purpose of this study was to develop a recombinant 
FVIII producing stable cell lines and monoclonal anti-
bodies for affinity purification of the secreted protein.
expression constructs bearing completely sequence-
verified cDnA’s of full-length human FVIII and a B-
domain deletion variant of human FVIII were obtained. 
Stably transfected cell pools were obtained; the BDD-
FVIII variant showed a vastly increased level of secre-
tion and was used for methotrexate-driven transgene 
amplification and subsequent cell cloning. A clonal cell 
line DG-BDDFVIII-18, capable of stable secretion of 
BDD-FVIII at the 500 Iu/l level, was established. the 
target protein in the conditioned medium was found to 
be biologically active and almost entirely processed into 
its two-chain mature form. the cell line was obtained 
without the use of animal-origin substances and stably 
grows in a chemically defined medium as a suspension 
culture. Monoclonal antibodies toward the heavy chain 
of BDD-FVIII, suitable for affinity purification of the 
target protein in native form, were obtained. 
thus, both of the major components of the industrial 
FVIII production process were created – the animal-
origin free clonal cell line and monoclonal antibodies for 
the affinity purification step. Generation of more pro-
ductive clonal cell lines and overall FVIII production 
process development will be studied subsequently.   
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